All manuscripts
Publications TCR T Cells G-Rex®24 Well Plate G-Rex®500M G-Rex®6 Well Plate

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial

Published Journal Molecular Therapy

Share
81 pages T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial — Molecular Therapy, 2026

Overview

Single-arm phase 1/2 trial NCT04146298 treated five recurrent pancreatic cancer patients with autologous T cells engineered with an HLA-A*11:01-restricted KRAS G12V TCR; three had repeat infusions. Products were rapidly expanded in G-Rex® 500 flasks and rested in G-Rex® 24-well plates (Wilson Wolf).

What this paper found

Autologous T cells engineered with an HLA-A*11:01-restricted KRAS G12V-specific TCR were tolerable in five patients with recurrent pancreatic cancer, and one patient had a complete response. In this single-arm phase 1/2 trial, patients received non-myeloablative lymphodepletion before infusion of products made by lentiviral transduction and a rapid expansion step, without IL-2 administration. Grade 3 or higher events were mainly lymphodepletion-related hematologic toxicities, with no grade 3 or higher cytokine release syndrome. The complete response lasted 5.5 months; two other patients had short-term stable disease. Retreatment gave no clinical responses, and hyper-acute rejection in some patients was likely caused by antibodies against the TCR induced by earlier infusions. Persistence varied; in one patient TCR-T cells were detectable for more than 190 days.

Note: Small single-arm study of five patients; the authors state that treatment of additional patients is required to determine efficacy.

We did not administer IL-2 in this study to minimize toxicities and test the therapeutic potential of our TCR-T in the absence of exogenous IL-2 support. — Xiongfei Xu, Haihui Gu, Zhanshan Cha, Bin Zhang, Shuai Yuan, Xiuwen Ding, Lei Gao, Suizhi Gao, Xinqian Wu, Lingyun Gu, Jianye Huang, Jianling Hao, Penghao Li, Yikai Li, Xiaochao Kang, Xiaohan Shi, Xiaoyi Yin, Huan Wang, Bo Li, Meilong Shi, Wei Jing, Kailian Zheng, Chunhong Zheng, Yi-Ping Shih, Cong Wu, Chenggang Zheng, Baohua Qian, Gusheng Tang, Jianmin Yang, Shiwei Guo, Eric Tran, Gang Jin, Molecular Therapy

Study details

Authors
Xiongfei Xu, Haihui Gu, Zhanshan Cha, Bin Zhang, Shuai Yuan, Xiuwen Ding, Lei Gao, Suizhi Gao, Xinqian Wu, Lingyun Gu, Jianye Huang, Jianling Hao, Penghao Li, Yikai Li, Xiaochao Kang, Xiaohan Shi, Xiaoyi Yin, Huan Wang, Bo Li, Meilong Shi, Wei Jing, Kailian Zheng, Chunhong Zheng, Yi-Ping Shih, Cong Wu, Chenggang Zheng, Baohua Qian, Gusheng Tang, Jianmin Yang, Shiwei Guo, Eric Tran, Gang Jin
Institution
Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China · Shanghai Institute of Pancreatic Diseases, Changhai Hospital, Naval Medical University, Shanghai, China · Department of Transfusion Medicine, Changhai Hospital, Naval Medical University, Shanghai, China · Department of Hyperbaric Medicine, Changhai Hospital, Naval Medical University, Shanghai, China · Clinical Research Center, Changhai Hospital, Naval Medical University, Shanghai, China · Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China · Frontiers Science Center for Cancer Integrative Omics, International Cancer Institute, Peking University, Beijing, China · Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
Journal
Molecular Therapy
Year
2026
PMID / PMC
PMID: 41814655 · PMC
G-Rex® model(s)
G-Rex®24 Well Plate, G-Rex®500M, G-Rex®6 Well Plate
Cell type(s)
TCR T Cells
Application area
Solid tumor

How G-Rex® was used

After stimulation with TransAct and IL-2 and lentiviral transduction, cells were transferred the next day to a G-Rex® 6-well plate and cultured further. The infusion product was then made by a 10- to 17-day rapid expansion in a G-Rex® 500 flask with irradiated healthy donor PBMC feeder cells, 30 ng/mL anti-CD3 (OKT3) and 3,000 IU/mL IL-2, and harvested for patient treatment. Thawed infusion product was rested overnight in a G-Rex® 24-well plate before functional assays.

Explore related

Full citation

Xu X, Gu H, Cha Z, et al. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Mol Ther. 2026;34(7):4001-4020.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →